Related Videos
Video
Kidney Cancer Highlights from ASCO 2025
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2025.
Video
ARC-20 Study Presented by Toni Choueiri, MD.
Toni Choueiri, MD, of Dana-Farber Cancer Institute presents first results from the ARC-20 trial evaluating casdatifan (HIF-2 inhibitor) + cabozantinib (VEGF TKI) in metastatic clear cell kidney cancer.
Video
Checkmate 214 Presented by Toni Choueiri, MD.
Dr. Toni Choueiri shares groundbreaking 9-year results from the CHECKMATE-214 trial.
Video
Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan
Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma.
Video
Toni Choueiri, MD Discusses Kidney Cancer JAVELIN 101
Kidney cancer research at ASCO24: Final analysis in JAVELIN Renal 101 trial confirms the efficacy and manageable safety profile of avelumab plus axitinib versus sunitinib in patients with advanced kidney cancer. Dana-Farber's Toni Choueiri, MD, explains more.
Video
Toni Choueiri, MD Provides Kidney Cancer CLEAR Trial biomarker analysis
Biomarker analysis in the phase 3 CLEAR trial shows biomarkers don't impact the superiority of lenvatinib plus pembrolizumab versus sunitinib as a first-line therapy in patients diagnosed with advanced kidney cancer.
Video
Kidney Cancer Highlights from ESMO 2023
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ESMO 2023.
Video
ASCO 2023: Kidney Cancer Highlights Presented By Vincent (Wenxin) Chu, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2023.
Video
ASCO 2023: Kidney Cancer Research Presented by Toni Choueiri, MD
We learn from negative study results as well as from positive ones. Phase 3 study by Dana-Farber's Toni Choueiri, MD, shows that rechallenge with PD-L1 inhibitors in second-line therapy for advanced kidney cancer has no benefit.